Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0013072,
umls-concept:C0018242,
umls-concept:C0018563,
umls-concept:C0040252,
umls-concept:C0040259,
umls-concept:C0064113,
umls-concept:C0087111,
umls-concept:C0201734,
umls-concept:C0205197,
umls-concept:C0205210,
umls-concept:C0459471,
umls-concept:C0679133,
umls-concept:C1274040,
umls-concept:C1556116,
umls-concept:C1556117,
umls-concept:C1707455,
umls-concept:C1979963,
umls-concept:C2003903,
umls-concept:C2348557
|
| pubmed:issue |
1
|
| pubmed:dateCreated |
1992-5-14
|
| pubmed:abstractText |
Itraconazole is an orally active triazole antifungal which has been compared to griseofulvin in a number of double-blind trials. In dermatophytosis with a non-fixed treatment regimen for a maximum of 3 months, itraconazole 100 mg o.d. has produced a 100% mycological cure rate as compared with a 67% rate with griseofulvin 500 mg o.d. (p less than 0.01). Based on the pharmacokinetic profile, 100 mg itraconazole daily was then compared with 500 mg ultramicronized griseofulvin daily using a fixed treatment schedule of 15 days in tinea corporis and/or cruris and 30 days in tinea pedis and/or manus. In all studies in tinea corporis/cruris (n = 277), the superiority of itraconazole was shown for the clinical outcome at the last follow-up visit 2 weeks post-therapy (88 vs. 69%, p less than 0.01) and in the mycological outcome at the last follow-up visit (81 vs. 65%, p less than 0.05). In tinea pedis/manus (n = 210), the clinical response was virtually the same for the two treatment groups, but the most important finding was the mycological outcome with a significantly better result in favor of itraconazole at the end of treatment (77 vs. 61%, p less than 0.05) even more pronounced at the follow-up visit (85 vs. 48%, p less than 0.01). We conclude that itraconazole 100 mg daily in the treatment of tinea corporis/cruris and in tinea pedis/manus is significantly more effective than 500 mg griseofulvin daily when fixed treatment regimens are used. Furthermore, the best results are obtained with itraconazole 2-3 weeks after the end of treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1018-8665
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
184
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
45-50
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1313717-Adolescent,
pubmed-meshheading:1313717-Adult,
pubmed-meshheading:1313717-Aged,
pubmed-meshheading:1313717-Antifungal Agents,
pubmed-meshheading:1313717-Child,
pubmed-meshheading:1313717-Child, Preschool,
pubmed-meshheading:1313717-Double-Blind Method,
pubmed-meshheading:1313717-Drug Administration Schedule,
pubmed-meshheading:1313717-Female,
pubmed-meshheading:1313717-Follow-Up Studies,
pubmed-meshheading:1313717-Griseofulvin,
pubmed-meshheading:1313717-Humans,
pubmed-meshheading:1313717-Itraconazole,
pubmed-meshheading:1313717-Ketoconazole,
pubmed-meshheading:1313717-Male,
pubmed-meshheading:1313717-Middle Aged,
pubmed-meshheading:1313717-Tinea
|
| pubmed:year |
1992
|
| pubmed:articleTitle |
Itraconazole compared with griseofulvin in the treatment of tinea corporis/cruris and tinea pedis/manus: an interpretation of the clinical results of all completed double-blind studies with respect to the pharmacokinetic profile.
|
| pubmed:affiliation |
Department of Dermatology, University of Louvain, Brussels, Belgium.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|